Dowling & Yahnke LLC raised its stake in shares of Gilead Sciences (NASDAQ:GILD) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,818 shares of the biopharmaceutical company’s stock after buying an additional 1,625 shares during the quarter. Dowling & Yahnke LLC’s holdings in Gilead Sciences were worth $3,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. Welch Investments LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $144,000. Hanson & Doremus Investment Management grew its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter valued at approximately $147,000. 77.91% of the stock is owned by institutional investors and hedge funds.
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $224,376,112.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 426,934 shares of company stock valued at $33,847,101. Corporate insiders own 1.30% of the company’s stock.
A number of equities research analysts have issued reports on GILD shares. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, December 11th. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. Credit Suisse Group lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and raised their target price for the company from $74.35 to $80.00 in a report on Wednesday, December 20th. Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, December 21st. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $88.61.
NASDAQ GILD traded down $1.41 on Friday, hitting $73.41. 6,434,206 shares of the stock were exchanged, compared to its average volume of 6,802,121. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $97,554.05, a price-to-earnings ratio of 8.58, a PEG ratio of -1.72 and a beta of 1.19. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the firm earned $2.70 earnings per share. Gilead Sciences’s quarterly revenue was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences will post 6.21 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.11%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
TRADEMARK VIOLATION NOTICE: “Dowling & Yahnke LLC Purchases 1,625 Shares of Gilead Sciences (GILD)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/dowling-yahnke-llc-has-3-50-million-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.